Biotechnology | HIV | NIH
Early HIV diagnosis and treatment important for better long-term health outcomes
On Oct. 24, 2022, the National Institutes of Health announced that starting antiretroviral treatment (ART) early in the…
Biotechnology | HIV | NIH | Vaccine
Three-dose hepatitis B vaccine regimen protected people with HIV
On Oct. 20, 2022, the National Institutes of Health announced that a three-dose course of the hepatitis B…
WHO recommended long-acting cabotegravir for HIV prevention
On Jul. 28, 2022, the World Health Organization (WHO) released new guidelines for the use of long-acting injectable…
Patient with HIV achieved remission following stem cell transplant
On Jul. 27, 2022, City of Hope announced that a 66-year-old man who was diagnosed with HIV in…
IAVI and Moderna launched first-in-Africa clinical trial of mRNA HIV vaccine development program
On May 18, 2022, Moderna and the nonprofit scientific research organization IAVI announced that the first participant screenings…
IAVI and Moderna partnered to tackle broad global health priorities using mRNA for vaccines and antibodies
On Apr. 7, 2022, Moderna and IAVI announced a collaboration to employ mRNA technology to meet the challenge…
Johnson & Johnson announced acquisition of Tibotec-Virco NV for $320 million in cash and debt
On Mar. 18, 2002, Johnson & Johnson announced an agreement to acquire all of the assets of Tibotec-Virco…
COVID-19 | HIV | NIH | Non-Profit Research | Vaccine
NIH launched clinical trial of three mRNA HIV vaccines
On Mar. 14, 2022, researchers from the National Institute of Allergy and Infectious Diseases (NIAID) announced they had…
Researchers documented third known case of HIV remission involving stem cell transplant
On Feb. 15, 2022, a woman with HIV who received a cord blood stem cell transplant to treat…
Anixa Biosciences and MolGenie announced early potency analysis of SARS-CoV-2 protease inhibitor
On Jan. 24, 2022, Anixa Biosciences announced that the company and its partner, MolGenie, had synthesized a compound…
Hologic added Aptima SARS-CoV-2 assay to its Global Access Initiative in resource-limited countries
On Jan 5, 2022, Hologic the addition of the Aptimaﾮ SARS-CoV-2 assay to its Global Access Initiative, a…
NIH researchers identified how two people controlled HIV after stopping treatment
On Oct. 29, 2021, research led by scientists at the National Institutes of Health announced they had identified…
Biotechnology | FDA | HIV | Therapeutics
U.S. FDA approved expanded indication of Gilead’s Biktarvy for Treatment of HIV-1 in pediatric populations
On Oct. 18, 2021, Gilead Sciences announced that the Food and Drug Administration had approved a new low-dose…
Biotechnology | COVID-19 | HIV | Life Science History | Non-Profit Research | Polio | Therapeutics | Vaccine | WHO
WHO bestowed posthumous award on the late Henrietta Lacks
On Oct. 13, 2021, the World Health Organization (WHO) honoured the late Henrietta Lacks with a WHO Director-General’s…
COVID-19 | Disease | HIV | Measles | Medicine | Pharmaceutical | Therapeutics | Vaccine
Resilience collaborated with Children’s Hospital of Philadelphia to develop next-gen biomanufacturing technologies
On Oct. 12, 2021, National Resilience announced a strategic collaboration with Children’s Hospital of Philadelphia (CHOP) to implement…
Biotechnology | COVID-19 | Genomics | HIV | Vaccine
Winners of 2022 Breakthrough Prizes In Life Sciences announced
On Sept. 22, 2021, the Breakthrough Prize Foundation and its founding sponsors announced the 2022 winners of the…
Biotechnology | HIV | NIH
NIH awarded more than $20 million to international HIV database centers
On Jul. 22, 2021, the National Institutes of Health announced it had renewed grants to seven regional centers…
CytoDyn received first order from Chiral Pharma for use of Leronlimab for COVID-19 patients in the Philippines
On Jun. 1, 2021, CytoDyn announced that Chiral Pharma in the Philippines placed its first purchase order for…
Biotechnology | HIV | Therapeutics | Vaccine
Oregon Health & Science University researchers unlocked HIV vaccine candidate’s mysteries 20 years later
On Mar. 25, 2021, about two decades after first devising a new kind of vaccine, Oregon Health &…
First-in-human clinical trial confirmed novel HIV vaccine approach
On Feb. 3, 2021, IAVI and Scripps Research announced a phase 1 clinical trial testing a novel vaccine…
Antibody infusions prevented acquisition of some HIV strains, NIH studies found
On Jan. 26, 2021, NIH researchers announced that an investigational anti-HIV antibody delivered intravenously once every eight weeks…
FDA approved first extended-release, injectable drug regimen for adults living with HIV
On Jan. 21, 2021, the FDA approved Cabenuva (cabotegravir and rilpivirine, injectable formulation) as a complete regimen for…
Janssen announced FDA approval of CABENUVA, the first long-acting HIV treatment regimen
On Jan. 21, 2021, Janssen Pharmaceutical announced the FDA had approved CABENUVA (consisting of Janssenﾒs rilpivirine and ViiV…
UC Berkeley scientists mapped coronavirus protein linked to disease severity
On Jan. 12, 2021, UC Berkeley HIV researchers announced that they had determined the atomic structure of a…
Biotechnology | COVID-19 | HIV | Influenza | Vaccine
Moderna announced three new development programs in infectious disease vaccines
On Jan. 11, 2021, Moderna announced that it was expanding its pipeline of innovative vaccines with three new…
NIH announced restructured HIV clinical trials networks
On Nov. 30, 2020, The National Institute of Allergy and Infectious Diseases (NIAID) announced the clinical investigators and…
Viatris announced FDA tentative approval of pediatric formulation of Dolutegravir under PEPFAR
On Nov. 23, 2020, Viatris announced tentative approval from the FDA for a New Drug Application for pediatric…
Aptima HIV-1 Quant Dx assay receivds additional FDA approval for use as aAid in diagnosis of HIV infection
On Nov. 30, 2020, Hologic announced that the FDA had approved a diagnostic claim for its HIV-1 (human…
Biotechnology | COVID-19 | Diagnostics | HIV
Viruses shown to evolve as a result of different immune responses in different ethnic populations
On Nov. 19, 2020, University of Oxford researchers announced that research into the HIV-1 virus had shed light…
Gilead announced long-acting HIV-1 capsid inhibitor, lenacapavir, achieved primary endpoint in phase 2/3 study
On Nov. 18, 2020, Gilead Sciences announced topline results from the Phase 2/3 CAPELLA trial evaluating the company’s…